Relationship of Soluble RAGE and RAGE Ligands HMGB1 and EN-RAGE to Endothelial Dysfunction in Type 1 and Type 2 Diabetes Mellitus

Abstract

Aims:

Receptor for advanced glycation endproducts (RAGE) plays the essential role in the pathogenesis of diabetic vascular complications. The aim of the study was to compare concentration of soluble RAGE and its ligands (EN-RAGE and HMGB1) with different biochemical parameters in Type 1 (T1DM) and Type 2 (T2DM) diabetes mellitus.

Methods:

Total number of 154 persons (45 T1DM, 68 T2DM, 41 controls) was examined and concentrations of sRAGE, EN-RAGE and HMGB1 were measured and compared to diabetes control, albuminuria, cell adhesion molecules and metalloproteinases (MMPs).

Results:

Mean serum sRAGE concentration was higher in T1DM as compared to controls (1137±532 ng/l vs. 824±309 ng/l, p<0.01). Similarly, EN-RAGE was significantly higher in both diabetic groups (p<0.001) and HMGB1 concentrations were elevated in T2DM patients (p<0.01). Significant relationship was found between MMP9 and HMGB1 and EN-RAGE in diabetic patients. Inverse relationship was observed between MMP2 and MMP9 in both types of diabetic patients (r= − 0.602, p<0.002 and r= − 0.771, p<0.001). Significant positive correlation was found between sRAGE and ICAM-1, VCAM-1 or vWF (p<0.01 to p<0.001).

Conclusion:

We conclude that serum sRAGE and RAGE ligands concentrations reflect endothelial dysfunction developing in diabetes.

Key words

soluble RAGE - RAGE ligands - endothelial dysfunction - diabetes mellitus - MMPs

• References

• 1 Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009; 52: 2251-2263
• 2 Biscetti F, Straface G, De Cristofaro R et al. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 2010; 59: 1496-1505
• 3 Gaens KHJ, Ferreira I, van der Kallen CJH et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 2009; 94: 5174-5180
• 4 Gul OO, Tuncel E, Yilmaz Y et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabo-Clin Exp 2010; 59: 64-69
• 5 Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901
• 6 Jang Y, Kim JY, Kang SM et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabo-Clin Exp 2007; 56: 199-205
• 7 Kadoglou NP, Daskalopoulou SS, Perrea D et al. Matrix metalloproteinases and diabetic vascular complications. Angiology 2005; 56: 173-189
• 8 Kalousova M, Bartosova K, Zima T et al. Pregnancy-associated plasma protein A and soluble receptor for advanced glycation end products after kidney transplantation. Kidney Blood Press R 2007; 30: 31-37
• 9 Kalousova M, Hodkova M, Kazderova M et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-411
• 10 Kalousova M, Jachymova M, Mestek O et al. Receptor for advanced glycation end products – soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 2007; 22: 2020-2026
• 11 Kankova K, Kalousova M, Hertlova M et al. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch Physiol Biochem 2008; 114: 111-119
• 12 Katakami N, Matsuhisa M, Kaneto H et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009; 204: 288-292
• 13 Katakami N, Matsuhisa M, Kaneto H et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Re 2008; 5: 190-197
• 14 Kosaki A, Hasegawa T, Kimura T et al. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocr Metab 2004; 89: 5423-5428
• 15 Kowluru RA, Kanwar M. Oxidative stress and the development of diabetic retinopathy: Contributory role of matrix metalloproteinase-2. Free Radic Biol Med 2009; 46: 1677-1685
• 16 Koyama H, Nishizawa Y. AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD?. Eur J Clin Invest 2010; 40: 623-635
• 17 Krechler T, Jachymova M, Mestek O et al. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem 2010; 43: 882-886
• 18 Marcovecchio ML, Giannini C, Dalton RN et al. Reduced endogenous secretory receptor for advanced glycation end products (esRAGE) in young people with Type 1 diabetes developing microalbuminuria. Diabetic Med 2009; 26: 815-819
• 19 Nawroth PP, Rudofsky G, Humpert P. Have we understood diabetes? New tasks for diagnosis and therapy. Exp Clin Endocrinol Diabet 2010; 118: 1-3
• 20 Osawa M, Yamamoto Y, Munesue S et al. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. BBA-Gen Subjects 2007; 1770: 1468-1474
• 21 Papazafiropoulou A, Perrea D, Moyssakis I et al. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J Diabetes Complicat 2010; 24: 20-27
• 22 Raucci A, Cugusi S, Antonelli A et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). Faseb J 2008; 22: 3716-3727
• 23 Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403
• 24 Skrha J, Prazny M, Hilgertova J et al. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol 2007; 63: 1107-1114
• 25 Skrha J, Stulc T, Hilgertova J et al. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol 2004; 493: 183-189
• 26 Sparvero LJ, Asafu-Adjei D, Kang R et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009; 7
• 27 Tam HL, Shiu SWM, Wong Y et al. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209: 173-177
• 28 Thrailkill KM, Bunn RC, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 2009; 35: 1-10
• 29 Vazzana N, Santilli F, Cuccurullo C et al. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009; 4: 389-401
• 30 Wang LJ, Lu L, Zhang FR et al. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail 2011; 13: 440-449
• 31 Wautier JL, Grossin N. sRAGE and esRAGE. Diabetes Metab 2008; 34: 631-
• 32 Yan SF, Du Yan S, Ramasamy R et al. Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med 2009; 41: 408-422
• 33 Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 2009; 87: 235-247
• 34 Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010; 79: 1379-1386
• 35 Yan XX, Lu L, Peng WH et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2009; 205: 544-548
• 36 Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010; 59: 249-255